Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 1
6(85.7%)
Phase 2
1(14.3%)
7Total
Phase 1(6)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06720987Phase 1Recruiting

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Role: lead

NCT07542704Phase 1Not Yet Recruiting

A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

Role: lead

NCT07406633Phase 2Recruiting

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

Role: lead

NCT06645886Phase 1Active Not Recruiting

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

Role: lead

NCT07207707Phase 1Recruiting

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

Role: lead

NCT06994806Phase 1Recruiting

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Role: lead

NCT06507306Phase 1Recruiting

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Role: lead

All 7 trials loaded